TrialBlood2022

Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE.

Jesus San-Miguel et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.